Loading…
NewAmsterdam Pharma Company N.V. is projected to rise to $44.77 by 2027, a +27% move from its current price of $35.26. NAMS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $34.40 | $35.27 | $36.16 | +0.03% |
| Jul 14 | $34.06 | $35.28 | $36.54 | +0.06% |
| Jul 15 | $33.80 | $35.29 | $36.84 | +0.08% |
| Jul 16 | $33.59 | $35.30 | $37.10 | +0.11% |
| Jul 17 | $33.40 | $35.31 | $37.33 | +0.14% |
| Jul 18 | $33.23 | $35.32 | $37.54 | +0.17% |
| Jul 19 | $33.08 | $35.33 | $37.73 | +0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $33.08 | $35.33 | $37.73 | +0.19% |
| Week 2 | $32.25 | $35.40 | $38.85 | +0.39% |
| Week 3 | $31.65 | $35.46 | $39.74 | +0.58% |
| Week 4 | $31.15 | $35.53 | $40.53 | +0.77% |
| Week 5 | $30.73 | $35.60 | $41.24 | +0.97% |
| Week 6 | $30.36 | $35.67 | $41.91 | +1.16% |
| Week 7 | $30.03 | $35.74 | $42.53 | +1.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.
NewAmsterdam Pharma is headquartered in Naarden, the Netherlands.
The asset is NewAmsterdam Pharma Company N.V. (NAMS). It trades at $36.99 per share and has a market capitalization of $4.32B. It ranks 1487. The forecast path suggests a bullish price trajectory, with 2026 average at $36.99 rising to $73.03 by 2030 and $355.89 by 2050, while intrayear maxima rise to as high as $646.42 by 2050.
A major floor 25.7% below — a decisive break under it would weaken the trend.
The nearest floor, 16.8% below — buyers have tended to step in here.
The nearest ceiling, 4.9% above — a clean break opens room to run.
A major ceiling 17.8% above — clearing it would confirm fresh momentum.
Key NAMS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAMS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.78 | Sell | $35.49 | Sell |
| MA 10 | $34.99 | Buy | $34.83 | Buy |
| MA 20 | $32.90 | Buy | $33.90 | Buy |
| MA 50 | $33.26 | Buy | $33.25 | Buy |
| MA 100 | $32.79 | Buy | $33.02 | Buy |
| MA 200 | $33.86 | Buy | $31.81 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.25 | Neutral |
| Stoch RSI (14) | 57.48 | Neutral |
| CCI (20) | 75.26 | Neutral |
| Williams %R (14) | -28.04 | Info |
| MACD (12,26,9) | 0.43 | Buy |
| ROC (12) | 12.29 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 71.96 | Neutral |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 2.80 | Buy |
| Ultimate (7,14,28) | 64.16 | Neutral |
| Momentum (10) | 3.53 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 36.27 | Sell |
| ADX (14) | 18.92 | Neutral |
| ATR (14) | 0.77 | Info |
Technical sentiment is BULLISH. RSI(14) is 70, with the 50-day SMA at $32.90 and the 200-day SMA at $33.73. The near-term range for the last 30 days runs from $31.16 to $43.91, with support at $29.33 and resistance at $36.99.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.43 | $35.26 | $44.06 | 0% | Neutral | |
| $35.94 | $44.77 | $58.81 | +27% | Bullish | |
| $42.53 | $54.33 | $73.85 | +54% | Bullish | |
| $49.24 | $64.22 | $89.66 | +82% | Bullish | |
| $52.48 | $69.71 | $99.54 | +98% | Bullish | |
| $53.00 | $71.59 | $104.26 | +103% | Bullish | |
| $59.07 | $81.02 | $120.10 | +130% | Bullish | |
| $65.22 | $90.77 | $136.73 | +157% | Bullish | |
| $75.82 | $106.98 | $163.55 | +203% | Bullish | |
| $85.98 | $122.93 | $190.52 | +249% | Bullish | |
| $120.93 | $183.47 | $301.24 | +420% | Bullish | |
| $204.81 | $343.73 | $614.13 | +875% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.43 | $35.26 | $41.99 | +0.00% |
| August 2026 | $29.88 | $35.18 | $42.47 | -0.22% |
| September 2026 | $30.51 | $36.16 | $44.10 | +2.77% |
| October 2026 | $30.81 | $36.70 | $45.15 | +1.51% |
| November 2026 | $29.84 | $35.71 | $44.24 | -2.70% |
| December 2026 | $29.39 | $35.33 | $44.06 | -1.07% |
Click any year to see its month-by-month NAMS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NewAmsterdam Pharma Company N.V.'s 2026 outlook centres on $35.26, within a $28.43 to $44.06 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NAMS could reach as high as $58.81, with a base case around $44.77 and support toward $35.94 — roughly +27% from $35.26. Buyers look set to stay in control over this stretch.
Expect NAMS to range from $42.53 to $73.85 through 2028. The $54.33 average target implies a +54% move from current prices. That is up +21% on the projected 2027 average. Momentum favours further upside here.
The NAMS price prediction for 2029 points to an average of $64.22 (low $49.24, high $89.66) — a potential gain of +82% on today's $35.26. Buyers look set to stay in control over this stretch.
In 2030, NAMS is projected to trade between $52.48 and $99.54, averaging $69.71 — a potential gain of +98% from today's $35.26. That is up +9% on the projected 2029 average. Momentum favours further upside here.
NewAmsterdam Pharma Company N.V.'s 2031 outlook centres on $71.59, within a $53.00 to $104.26 range. That is up +3% on the projected 2030 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NAMS could reach as high as $120.10, with a base case around $81.02 and support toward $59.07 — roughly +130% from $35.26. Momentum favours further upside here.
Expect NAMS to range from $65.22 to $136.73 through 2033. The $90.77 average target implies a +157% move from current prices. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NAMS price prediction for 2034 points to an average of $106.98 (low $75.82, high $163.55) — a potential gain of +203% on today's $35.26. Momentum favours further upside here.
In 2035, NAMS is projected to trade between $85.98 and $190.52, averaging $122.93 — a potential gain of +249% from today's $35.26. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NewAmsterdam Pharma Company N.V.'s 2040 outlook centres on $183.47, within a $120.93 to $301.24 range. That is up +49% on the projected 2035 average. That marks a +420% change versus current levels. Momentum favours further upside here.
By 2050, NAMS could reach as high as $614.13, with a base case around $343.73 and support toward $204.81 — roughly +875% from $35.26. Buyers look set to stay in control over this stretch.
Investing $1,000 in NAMS today (≈ 28.360749 NAMS) could be worth
$9,748.52
+$8,748.52 (+875%) by 2050 · US Dollar
Based on the average projected NAMS price of $343.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAMSwould be worth at today's price.
$1,000 invested in NAMS on Jul 10, 2025 (≈ 45.41326 NAMS) would be worth
$1,601.27
+$601.27 (+60.1%) today · 1.60× · US Dollar
Based on a NAMS entry price of $22.02 vs. today's $35.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $34.83 | $1,012.35 | +1.2% |
| 1 month ago | $29.33 | $1,202.18 | +20.2% |
| 3 months ago | $34.76 | $1,014.38 | +1.4% |
| 6 months ago | $32.69 | $1,078.62 | +7.9% |
| 1 year ago | $22.02 | $1,601.27 | +60.1% |
| All time (5.0y) ago | $9.74 | $3,620.12 | +262.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAMS forecast.
Our base-case forecast reaches $71.00 around 2031.
Implied market cap at $71.00: $8.3B
The multi-year forecast shows a bullish trajectory with rising averages and higher maxima. By 2026 the average is $36.99; by 2030 the average is $73.03, with a 2030 ROI of 97.4% and a bullish sentiment. By 2040 the average is $190.54 with a forecasted ROI of 415.1%.
By 2050 the average is $355.89 with a forecasted ROI of 862.1% and a bullish sentiment. These figures are estimates and not guarantees; actual results depend on market conditions and development progress.
Tap a question to reveal the answer.
The forecast shows avg $73.03 with min $54.56 and max $105.22; ROI 97.4% ; sentiment BULLISH.
The outlook shows bullish sentiment across 2027-2050, with 2027 avg $47.10, 2040 avg $190.54, and 2050 avg $355.89; ROI rises to 27.3% in 2027 and 862.1% in 2050. The 2026 average is $36.99 with ROI 0%. These are estimates, not guarantees.
The forecast max values reach $105.22 in 2030, $109.24 in 2031, $126.88 in 2032, and higher in later years, so surpassing $100 is plausible in several years.
Current price $36.99; Market cap $4.32B.
Sentiment is BULLISH; RSI14 is 70; SMA50 is $32.90; SMA200 is $33.73; 30-day range is $31.16-$43.91; support is $29.33 and resistance is $36.99.
NewAmsterdam Pharma Company N.V. Community Discussion
0Share your NewAmsterdam Pharma Company N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.